Decoding metabolic diseases through bacterial extracellular vesicles: mechanisms, diagnostics, and therapeutics.

IF 15 1区 生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Di Song, Wenhui Mo, Qiaoyu Deng, Yu Zeng, Yujie Zhang, Xiaoyan Ao, Liling Deng, Xiaoze Wang, Xiaoli Fan
{"title":"Decoding metabolic diseases through bacterial extracellular vesicles: mechanisms, diagnostics, and therapeutics.","authors":"Di Song, Wenhui Mo, Qiaoyu Deng, Yu Zeng, Yujie Zhang, Xiaoyan Ao, Liling Deng, Xiaoze Wang, Xiaoli Fan","doi":"10.1186/s12951-026-04826-z","DOIUrl":null,"url":null,"abstract":"<p><p>Metabolic diseases represent a class of chronic conditions characterized by disturbances in energy and material metabolism. These diseases primarily include obesity, metabolic dysfunction-associated steatotic liver disease, atherosclerosis, type 2 diabetes, osteoporosis, and polycystic ovary syndrome. A core pathological feature underlying their development is the mutual reinforcement between chronic low-grade inflammation and metabolic imbalance. The gut microbiota has been highlighted by recent research as a key regulator of host metabolism, while bacterial extracellular vesicles (BEVs) are emerging as critical mediators. BEVs transport bioactive molecules (proteins, lipids, nucleic acids) to facilitate microbiota-host crosstalk without direct contact. Pathogen-derived BEVs often exacerbate metabolic dysfunction via inflammation, while commensal/probiotic BEVs protect against disorders by enhancing intestinal barrier function and regulating immunity. Furthermore, owing to their high stability, easy penetration of biological barriers, and capacity to carry abundant cellular information, BEVs demonstrate broad application prospects as non-invasive diagnostic biomarkers for metabolic diseases and as natural or engineered targeted drug delivery vehicles. This review outlines the mechanisms and progress in the application of gut BEVs in metabolic diseases. It aims to deepen our understanding of host-microbiota interaction networks and support the development of novel intervention strategies for metabolic diseases.</p>","PeriodicalId":16383,"journal":{"name":"Journal of Nanobiotechnology","volume":"24 1","pages":""},"PeriodicalIF":15.0000,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688932/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanobiotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s12951-026-04826-z","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Metabolic diseases represent a class of chronic conditions characterized by disturbances in energy and material metabolism. These diseases primarily include obesity, metabolic dysfunction-associated steatotic liver disease, atherosclerosis, type 2 diabetes, osteoporosis, and polycystic ovary syndrome. A core pathological feature underlying their development is the mutual reinforcement between chronic low-grade inflammation and metabolic imbalance. The gut microbiota has been highlighted by recent research as a key regulator of host metabolism, while bacterial extracellular vesicles (BEVs) are emerging as critical mediators. BEVs transport bioactive molecules (proteins, lipids, nucleic acids) to facilitate microbiota-host crosstalk without direct contact. Pathogen-derived BEVs often exacerbate metabolic dysfunction via inflammation, while commensal/probiotic BEVs protect against disorders by enhancing intestinal barrier function and regulating immunity. Furthermore, owing to their high stability, easy penetration of biological barriers, and capacity to carry abundant cellular information, BEVs demonstrate broad application prospects as non-invasive diagnostic biomarkers for metabolic diseases and as natural or engineered targeted drug delivery vehicles. This review outlines the mechanisms and progress in the application of gut BEVs in metabolic diseases. It aims to deepen our understanding of host-microbiota interaction networks and support the development of novel intervention strategies for metabolic diseases.

通过细菌细胞外囊泡解码代谢疾病:机制、诊断和治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Nanobiotechnology
Journal of Nanobiotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-NANOSCIENCE & NANOTECHNOLOGY
CiteScore
13.90
自引率
4.90%
发文量
493
审稿时长
16 weeks
期刊介绍: Journal of Nanobiotechnology is an open access peer-reviewed journal communicating scientific and technological advances in the fields of medicine and biology, with an emphasis in their interface with nanoscale sciences. The journal provides biomedical scientists and the international biotechnology business community with the latest developments in the growing field of Nanobiotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书